The application of modern MS and LC techniques (e.g., UHPLC-MS), has greatly increased the potential of this technology for �global� metabolic profiling (metabotyping) as used in metabonomics/metabolomics in the search for biomarkers. The ability to provide broad metabolite profiles of biological fluids and tissue extracts can be used to advantage in characterising disease rodent models of disease, and in monitoring response to therapy (including potential toxicity). Such methods offer opportunities in drug discovery and development, and also perhaps in translation to patients. A range of applications of different types of metabolic profiling will be used to illustrate some of the benefits of this �global� approach to metabolic profiling and also highlight the difficulties. One particular problem is not the detection of metabolites that might be biomarkers of a particular/disease conditions, but identifying them, and then understanding what they are actually biomarkers of. At its simplest the question that these metabolites pose is, are they really a set of useful mechanistic biomarkers delivering real insight to the biology being studied?, or just a more general, non-specific, response?, or worse an artefact of the experimental design!.The potential of some emerging developments in analytical technology will be considered, together the approaches that can be taken once you have found your biomarker such as systems biology modelling and the construction of a combined systems biology/PBPK model that provides testable predictions.  .

Metabotyping: Metabolic phenotypes for characterising rodent models of disease

247th National Meeting (2014)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.